Aim The study aimed to establish the oncological outcome of patients who opted for close surveillance with or without adjuvant chemoradiotherapy rather than radical surgery after local excision (LE) of early rectal cancer.
Introduction
The UK National Bowel Cancer Screening Programme is increasing the proportion of colorectal cancers diagnosed at an early stage. Logan et al. [1] published the results of the first 1 million screened patients and reported 42% of screen detected colorectal cancers to be Stage I. Early rectal cancer (ERC) can be defined as a Stage I, Dukes A or TNM T1 or T2 N0 cancer. Local excision (LE) not compromising the oncological outcome could potentially be offered to the majority of such patients. The technical options for LE vary depending on the facilities and expertise available in the unit and include endoscopic mucosal or submucosal resection and transanal surgical techniques including transanal endoscopic microsurgery (TEM) and transanal resection (TAR). About half of sessile malignant polyps resected have adverse features on histopathological assessment such as poor differentiation, mucinous-type histology, lymphovascular invasion or direct invasion deep into the submucosal layer [2] . Such features are associated with a 20% rate of lymph node metastasis. In this circumstance the current standard of practice is to offer a radical resection to avoid leaving residual locoregional disease [3] . An anterior resection with total mesorectal excision after LE may be difficult owing to inflammation and fibrosis especially if it is delayed. Furthermore, patients may not accept such major surgery with its mortality and morbidity particularly if there is a high probability that there will be no residual tumour in the resection specimen.
Investigating ERC to define the role of both LE and adjuvant therapy was the most important research priority agreed by the recent Delphi survey of over 900 colorectal surgeons of the Association of Coloproctology of Great Britain and Ireland (ACPGBI) [4] . Previously published data do not support the use of adjuvant chemoradiotherapy (CRT) after LE of high risk T1 or T2 cancers as an alternative to completion major resection. Paty et al. [5] report that adjuvant CRT after LE only delays the time to local recurrence from 1.1 years to 2.1 years which was 7% for T1 and 24% for T2 in their unit. The prospective phase II study by Greenberg et al. [6] reported 10 year rates of disease-free survival of 75% and 64% for patients with locally excised T1 and T2 lesions. This study, however, did not use MRI or ultrasound to stage the tumour before treatment but instead relied on CT, carcinoembryonic antigen estimation and clinical assessment [6] , and the protocol of follow-up after LE was not stipulated.
In recent years there have been improvements in the assessment of ERC and surveillance by high resolution MRI and also in the technique of LE. In our practice patients with ERC treated by LE undergo high resolution MRI to identify any extramural macroscopic disease, such as malignant lymph nodes or extramural vascular invasion. In accordance with national guidelines the policy in our hospital was to offer completion radical surgery if adverse histology features were reported after LE [3] . If radical surgery was declined we gave patients the alternative option of adjuvant CRT and intensive follow-up. Here we report on our experience, our surveillance protocol and the oncological outcomes of such patients with adverse histology who opted for follow-up with or without adjuvant therapy rather than completion radical surgery.
Method Patients
The study was registered as a service evaluation protocol and was approved by the hospital research data management and statistical unit. The Royal Marsden Hospital Rectal Cancer database was used to identify rectal cancer patients treated by LE from 2006 to 2015. All patients referred to the Royal Marsden multidisciplinary team MultiDisciplinary Team (MDT) who underwent LE or TEM for a rectal lesion proven to be adenocarcinoma were included. Patients were excluded if they had had preoperative CRT before LE. Thirty-six consecutive patients were found applying the above-mentioned criteria, but two patients who had a piecemeal resection of a dysplastic adenoma with no confirmation of malignancy on histopathology were excluded from the final analysis. There were therefore 34 (22 male) patients of mean age 63 (39-83) years with an ERC who were eligible for analysis (Fig. 1) .
Local excision
LE was performed by TEM or TAR. The indications included diagnostic and therapeutic. It was carried out according to the preoperative features of the tumour as follows: (i) for tumours considered to be malignant with suspected invasion of less than the full thickness of the muscularis propria, a full thickness LE by TEM or TAR was carried out; (ii) for tumours not considered to be invasive on clinical assessment, an LE with submucosal or partial or full thickness resection of the muscularis propria was performed with diagnostic intent, which then turned out to be the final treatment after histopathological examination of the surgical specimen.
The initial decision to perform LE was based predominantly on clinical assessment by digital rectal examination and rectoscopy and took into account the further factors of biopsy findings, size of lesion, patient preference, comorbidity and the feasibility of LE. The recommendation to offer radical surgery was based on the histopathological assessment of the LE surgical specimen taking into account known prognostic factors for recurrence after LE, in accordance with the ACPGBI guidelines [3] .
Adjuvant therapy
When completion surgery was declined by the patient but high risk features were considered present, adjuvant CRT was offered and 18/34 (53%) patients chose to have post LE external beam radiotherapy. Treatment was delivered by a conformal technique and the dose fractionation depended on the histopathological features and the estimated local recurrence risk. For patients with a clear margin on the LE specimen, where microscopic involvement of mesorectal lymph nodes was perceived as the main risk, 45 Gy in 25 fractions were given to the pelvis to include the mesorectum with concomitant capecitabine 825 mg/m 2 twice daily. Where there was an involved or close margin in the LE specimen, the tumour bed was boosted with further external beam radiotherapy delivering 9 Gy in five fractions to five patients and 5.4 Gy in three fractions to two patients.
Surveillance
Patients who received adjuvant CRT were followed up by the clinical oncology team at 3 monthly intervals for the first 2 years and thereafter at 6 monthly intervals to 5 years. An examination was carried out at every clinic visit with the results of MRI and carcinoembryonic antigen available at each visit. An annual CT scan was performed according to the usual protocol for patients with colorectal cancer. Patients having LE without adjuvant CRT were followed at similar intervals by the surgical team.
Magnetic resonance imaging
MRI was performed on 1.5 T MRI systems (Siemens, Erlangen, Germany) using a body-matrix phased array surface coil centred over the pelvis. After localizer sequences, high resolution T2 weighted turbo spin echo scans were acquired in the coronal and sagittal planes, followed by high resolution oblique-axial scans (perpendicular to the long axis of the rectum with 160 mm field of view, 3 mm slice thickness, no inter-slice gap and matrix 256 9 256). We used the routine reporting proforma of the radiological department at the Royal Marsden Hospital. The site of LE was determined by interpreting low signal intensity as the scar, regardless of whether it was confined to the rectal wall or extended into the mesorectum. Irregular intermediate signal intensity at the site was interpreted as showing the presence of residual or recurrent tumour. The craniocaudal length and thickness of the excised area was measured, assuming that any progressive increase in size or thickness of the scar or treated tumour site or new intermediate signal intensity within the mesorectum was suggestive of recurrence. If recurrence or persistence of tumour was suspected in the lumen or the mesorectum on either MRI or clinical assessment, the patient was discussed by the MDT.
Statistical analysis
Data were expressed as median and range or as a proportion of the denominator of 34 with 95% CI. Overall survival (OS) was calculated measured from the date of LE to the most recent follow-up date or death from any cause. The disease-free survival (DFS) was calculated from the date of surgery to the point of appearance of metastatic or local disease or cancer related death. Survival curves for OS and DFS were obtained using the Kaplan-Meier method. Patients without an event were censored at the last follow-up. A P value of < 0.05 was taken as being statistically significant. Statistical analysis was performed using SPSS version 23; IBM corporation, Armonk, New York, USA.
Results
Patients LE was undertaken in 34 patients. In 19 the procedure was diagnostic and in the remaining 15 patients it was therapeutic. Twelve (58%) of the 19 and 13 (82%) of the 15 patients had had a preoperative MRI. Six in the diagnostic group and three in the therapeutic group had TEM. Eighteen patients were referred from the local network of hospitals where MRI for ERC was agreed policy and of these 17 (94%) had had preoperative MRI (Table 1) .
Histopathology
The final histology of the 34 surgical specimens was as follows: pT1sm1À2, 16 (47%); pT1sm3, 10 (29%); pT2, 7 (21%); pT3b, 1 (3%) ( Table 2 ). The resection margin was less than 1 mm in 18 (53%) of the 34 specimens and 1-2 mm in 5 (15%) with missing data in 7 (21%). Intramural lymphovascular invasion was identified in 13 (38%). This increased with the depth of invasion being present in 28.5% of T1sm2 tumours, 40% of T1sm3 tumours and 57% of T2 tumours. Information on tumour budding status was missing in nine patients. Poorly differentiated tumours were found in 9% of cases and a further 23% showed mucin histology. Therefore of the 34 patients undergoing LE, 28 (82%) were categorized into the group of high or very high risk for local recurrence according to ACPGBI recommendations [3] .
Treatment
In 25 (73%) patients the lower border of the tumour was less than 6 cm from the anal verge. In 24 (71%) the MDT recommended abdominoperineal excision (APE) of the rectum. This was based on assessment of the potential surgical plane of dissection required to achieve clearance of more than 1 mm. Overall the MDT advised radical surgery or adjuvant CRT in 28 (82%) patients, but 18 opted to be treated by adjuvant CRT and surveillance and 10 declined CRT and chose clinical and MRI surveillance. In the patients opting for adjuvant CRT and close surveillance, the median interval from the LE to starting CRT was 62.5 (30-136) days.
Patients were analysed in three groups according to the management strategy after LE. These included (i) 18 patients at high risk of local recurrence who received adjuvant CRT (group 1), (ii) 10 patients who opted for surveillance with no adjuvant CRT (group 2) and (iii) six patients at low risk for local recurrence (group 3). The median follow-up for all patients was 49 (19-121) months. The OS at 4.0 years was 100%. At a median follow-up interval of 49 (14-121) months (Table 3) none of the patients in management groups 1 and 3 developed local or distant recurrence. Meanwhile two patients who declined further treatment (the second group in the survival curve analysis) were identified as having residual extramural disease and macroscopic residual tumour at the site of LE on the first surveillance MRI and colonoscopy and underwent radical surgery. In both cases radical surgery, consisting of APE, was performed within 3 months after primary LE. The final histopathological examination of the surgical specimen confirmed pT3bN0R0 and T2N0R0 adenocarcinoma. None of these patients developed distant metastases. A further two patients of the second group developed local recurrence at 6 and 7 months after LE surgery, and 1 (10%) developed distant lung metastases at 11 months (Fig. 2) .
One patient experienced a local recurrence at 7 months after LE. Histopathological examination had shown a pT1sm2 tumour containing mucin. The patient had had no adjuvant CRT and an extramural mucinous recurrence was diagnosed on a routine follow-up MRI scan (Fig. 3) . The patient underwent APE for ypT2N0 tumour and remains under surveillance without pelvic recurrence or distant metastasis.
The other case of local recurrence occurred in a patient treated by LE for yT1sm3R1 moderately differentiated adenocarcinoma. Following the actual excision a defect in the rectal wall which appeared to be abutting the mesorectal fascia was seen. The patient declined any further treatment and underwent close surveillance. A 6 months MRI scan showed a new area of nodularity with intermediate signal intensity at the site of the surgical scar. The patient subsequently received CRT which was commenced 247 days after LE. An MRI scan immediately following this treatment showed a good response, but a subsequent MRI within 3 months of the end of adjuvant CRT showed tumour regrowth which was confirmed by rectal biopsy to be carcinoma. The patient eventually underwent an APE and has no evidence of recurrent or metastatic disease at 82 months from the initial LE.
One patient from the second group developed a pulmonary metastasis within 11 months after LE of a poorly differentiated pT1sm3 adenocarcinoma. The metastasis was resected with no further sites of relapse in the 36 months following LE.
Discussion
The present study demonstrated that patients undergoing LE of an ERC with histopathological features indicating a high risk of recurrence who opted for adjuvant CRT and close surveillance rather than major surgery had no recurrence either local or distant and a 3 year disease-free survival of 100%. In contrast patients with a high risk locally excised tumour, who chose close surveillance but no further treatment, experienced a local recurrence rate of 40%. Overall 22 (92%) of the 24 patients included in the study successfully avoided a recommended APE for at least 3 years. We acknowledge that the study is not a prospective trial but rather an analysis of a prospective patient database. We do not have data on the outcome of patients with tumours of a similar stage who opt for completion major surgery, as in our practice most patients opt for surveillance. We also do not have experience of significant numbers of patients undergoing surveillance without adjuvant therapy. Nevertheless, the safety of completion major resection after LE of ERC with a high histopathological risk of recurrence has been reported by others to be very low. Thus Hahnloser et al. reported a local recurrence rate of 3% after completion major resection following the LE of high risk ERC which was no different from the 5% rate of local recurrence after primary radical surgery [7] . Radical surgery in ERC after a previous LE performed by whatever technique can be technically difficult owing to the presence of fibrosis and inflammation. Adjuvant CRT in patients at high risk of local recurrence after LE is not included in the published treatment guidelines and appears to have been considered an alternative option rather than standard treatment as there are insufficient data to support this approach. The most recently published systematic review on ERC included 10 studies that evaluated LE combined with adjuvant CRT. This showed that at a range of 30.5-115.2 months median OS was 75% (66%-80.6%) and DFS was 74% (64%-85.2%) [8] , although some of the older studies included in the review had not used modern MRI for the initial assessment and the subsequent follow-up.
The present study has shown that when a patient having LE of a high risk ERC declines recommended major surgery, close surveillance is effective. Thus the single patient who developed metastatic disease was identified in our surveillance programme and underwent early metastectomy and the four patients with local Post TEM scar 7 months after 10 months after Figure 3 A post-transanal endoscopic microsurgery (TEM) MRI shows a well-defined scar (yellow arrow) at the site of excision of a low rectal pT1sm2 tumour containing mucin. At 7 months after surgery an MRI scan demonstrated an area of extramural hyperintense signal at the site of the TEM scar, highly suspicious of local recurrence. Three months later disease progression was noted and extramural mucinous mass had now infiltrated the rectal wall at the site of the scar. A biopsy confirmed recurrence. MRI had successfully identified relapse before clinical evidence of recurrence by 7 months.
recurrence underwent APE with curative intent. In all of these patients local recurrence was identified on high resolution MRI and confirmed by biopsy. MRI is superior to endoscopy for assessing the LE scar during follow-up as it can visualize the extraluminal component and the whole mesorectum and pelvic side wall can be monitored. This may account for the improved safety and survival seen in the present series. Recurrence has been reported up to 7 years after LE and adjuvant therapy, but the vast majority of relapses occur in the first 3 years [5, 6] . Contemporary trials evaluating LE also reported the oncological end-points at 3 years. The findings of this study therefore raise the possibility of discussing surveillance rather than radical surgery as an initial option in patients with a locally excised ERC, even one with high risk histopathological features.
Larger prospective studies with longer follow-up are needed, but if the results of the present study are confirmed they would be a significant advance in the treatment of ERC. Institutions intending to study the question of management after LE for ERC should be confident of the quality of their tumour staging and surveillance programmes. For a rectal adenoma removed endoscopically and found to contain unexpected malignancy, the results of the present study agree with the literature that further therapy, whether CRT or surgery, can be avoided in a proportion of patients. It also suggests, however, that an ERC treated by LE which contains adverse histopathological features should be considered for adjuvant CRT rather than having major surgery. Whatever option is chosen, close surveillance should be performed including high resolution pelvic MRI to exclude any residual or recurrent intramural and extramural disease.
It is important to recognize that a comparable oncological outcome after subsequent major surgery or surveillance with or without CRT must include the consideration of other factors including mortality, morbidity, function and quality of life. Selective adjuvant CRT based on carefully documented histopathology together with a policy of careful MRI-based surveillance in patients having LE for an ERC appears to be feasible and warrants evaluation by future research.
